NCT04663386

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway; A Retrospective, Observational Study to Evaluate the Impact on Disease Control in Patients With Asthma and/or Chronic Obstructive Pulmonary Disease (COPD)

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 29 (actual)
• Sponsor: Orion Corporation, Orion Pharma · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.

Detailed description

In July 2018 Norwegian authorities decided to allow switch at pharmacy for dry powder inhalers (DPIs) containing budesonide-formoterol. Pharmacists are instructed to switch patients to the inhaler with the lowest price. The pharmacist will train the patient on how to use the new inhaler. All patients whose eligible inhaler switch occurred between 1st July 2018 and 1st March 2019 will be eligible for the study.

Conditions

• Asthma
• COPD

Interventions

Type	Name	Description
DRUG	Budesonide-Formoterol	Dry powder inhaler

Timeline

• Start date: 2020-12-10
• Primary completion: 2021-09-14
• Completion: 2021-09-14
• First posted: 2020-12-11
• Last updated: 2021-09-23

Locations

1 site across 1 country: Norway